Scandion Oncology A/S Logo

Scandion Oncology A/S

SCOL | ST

Overview

Corporate Details

ISIN(s):
DK0061031895 (+3 more)
LEI:
549300MPWDMQ5LZEGD09
Country:
Denmark
Address:
Fruebjergvej 3, 2100 København Ø
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Scandion Oncology A/S is a company under liquidation. Previously, it operated as a clinical-stage biotechnology company focused on overcoming cancer drug resistance. The company's mission was to develop first-in-class, oral add-on drugs to revert resistance to existing cancer treatments and improve patient outcomes. Its primary development asset was the lead compound SCO-101, which aimed to enhance the efficacy of chemotherapy in patients who had developed treatment resistance. The company's research was centered on creating a pipeline of drugs targeting various molecular drug resistance mechanisms in cancer cells.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Scandion Oncology A/S. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Scandion Oncology A/S filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Scandion Oncology A/S via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
VERICI DX PLC Logo
AI-powered diagnostic tests for the kidney transplant market, predicting organ rejection and injury.
United Kingdom VRCI
Vicore Pharma Holding Logo
Develops AT2 receptor drugs and a digital therapeutic for pulmonary fibrosis.
Sweden VICO
Vivoryon Therapeutics N.V. Logo
Develops small molecule therapies for severe age-related, inflammatory, and neurodegenerative diseases.
Germany VVY
R&D in renewable energy & manufacturing specialized tools for automotive & engineering.
Slovakia N/A
Xintela AB Logo
Develops stem cell therapies and targeted antibody treatments for cancer and osteoarthritis.
Sweden XINT
Xlife Sciences AG Logo
A life sciences incubator commercializing early-stage academic research for healthcare markets.
Switzerland XLS
XTL Biopharmaceuticals Ltd. Logo
Acquires and develops late-stage therapeutics for autoimmune diseases.
Israel XTLB
Yoshi Innovation Spolka Akcyjna Logo
A tech fund incubating MedTech, biotech, and defense ventures with investment and IP protection.
Poland YOS
Zealand Pharma Logo
Develops innovative peptide medicines for metabolic and rare diseases.
Denmark ZEAL
Ziccum AB Logo
Licenses drying tech for thermostable vaccines & biologics, eliminating the cold chain.
Sweden ZICC